Vertex Paying 102% Premium: Is the Crinetics Deal Worth It?
Vertex is pursuing Crinetics with a substantial all-cash offer. This deep dive breaks down what the $10 billion bid m...
Biotech M&A
On this Biotech M&A tag page, you'll find coverage from 3 articles on Lilly, AbbVie, and other biotechs. See how deal activity could reshape stock moves and your financial planning.
8 articlesStock Market Today, June: Bio-Techne Surges on Merck Bid
A high-stakes cash bid from Merck KGaA sent Bio-Techne stock higher and sparked a flurry of trading. Here’s what inve...
AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
AbbVie Stock Jumped Today: Deal Sparks New Outlook for Investors
AbbVie stock jumped today after the company disclosed a bold acquisition of Apogee Therapeutics for $10.9 billion. Th...
Stock Market Today, June: AbbVie Cash Offer Boosts Apogee
A major biotech takeover bid sets the tone for today’s market. AbbVie’s cash offer for Apogee Therapeutics sent share...
AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Lilly Just Announced Infectious Disease Deals Diversification
Eli Lilly is shaking up its growth plan by expanding beyond obesity with new infectious disease initiatives. This art...
Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...